Capturing Genomic Evolution of Lung Cancers through Liquid Biopsy for Circulating Tumor DNA
Genetic sequencing of malignancies has become increasingly important to uncover therapeutic targets and capture the tumor’s dynamic changes to drug sensitivity and resistance through genomic evolution. In lung cancers, the current standard of tissue biopsy at the time of diagnosis and progression is...
Main Authors: | Michael Offin, Jacob J. Chabon, Pedram Razavi, James M. Isbell, Charles M. Rudin, Maximilian Diehn, Bob T. Li |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2017-01-01
|
Series: | Journal of Oncology |
Online Access: | http://dx.doi.org/10.1155/2017/4517834 |
Similar Items
-
Liquid Biopsy in Lung Cancer: Clinical Applications of Circulating Biomarkers (CTCs and ctDNA)
by: Minji Lim, et al.
Published: (2018-02-01) -
Mutated circulating tumor DNA as a liquid biopsy in lung cancer detection and treatment
by: Martyna Filipska, et al.
Published: (2021-06-01) -
Liquid biopsy in hepatocellular carcinoma: circulating tumor cells and circulating tumor DNA
by: Qianwei Ye, et al.
Published: (2019-07-01) -
Liquid Biopsy for Cancer: Circulating Tumor Cells, Circulating Free DNA or Exosomes?
by: Wei Zhang, et al.
Published: (2017-02-01) -
Circulating tumor DNA detection (liquid biopsy): prospects in oncology
by: N. V. Zhukov, et al.
Published: (2015-01-01)